# A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas

> **NCT02048488** · PHASE1,PHASE2 · COMPLETED · sponsor: **Tesaro, Inc.** · enrollment: 72 (actual)

## Conditions studied

- Solid Tumors
- Lymphomas

## Interventions

- **DRUG:** TSR-011

## Key facts

- **NCT ID:** NCT02048488
- **Lead sponsor:** Tesaro, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2016-09
- **Final completion:** 2018-06
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2019-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02048488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02048488, "A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02048488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*